Transplantation Overview

Principles

Definition

Transplantation is a research concept and methodological approach centered on the transfer of biological entities, structures, or conceptual systems from a source environment or organism to a recipient one. It systematically investigates the mechanisms facilitating this transfer, the subsequent integration and interaction within the recipient context, and the resulting functional or structural outcomes.

Ontological type

Core Mechanisms

Clinical Applications

Outcomes and Evaluation

Key developments

Key Figures

Histocompatibility Foundations era

E. Donnall Thomas [1] was a pioneering figure in transplantation during the Histocompatibility Foundations era, with affiliations at Harvard University [3] and Washington University in St. Louis [4]. His 1974 paper, CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,S [6], helped define how histocompatibility-driven graft acceptance and GVHD manifested in the clinical setting, underscoring why serologic matching and host-graft immune recognition mattered in this era. Peter J. Morris [2] contributed to serotyping for homotransplantation [7], advancing the practical tools for donor-recipient matching during this era, with affiliations at Harvard University [3] and the University of California, Los Angeles [5]. The era's histocompatibility foundations were shaped by serotyping for homotransplantation [7] and the clinical GVHD study [6], together guiding the codification of histocompatibility testing as a clinical prerequisite.

Pharmacologic Immunoregulation era

John E. Dick [1] conducted research at University of Toronto [3] and University of Colorado Denver [4] during this era. His work, exemplified by the 1994 paper 'A cell initiating human acute myeloid leukaemia after transplantation into SCID mice' [7], advanced understanding of immune interactions in transplantation and immunoregulation. Robert M. Merion [2] was affiliated with University of California, San Francisco [5] and Albert Einstein College of Medicine [6] during this period. The contributions of Merion are reflected in the papers 'Characteristics Associated with Liver Graft Failure: The Concept of a Donor Risk Index' [8] and 'The Survival Benefit of Liver Transplantation' [9], which informed donor assessment and demonstrated the survival advantage of transplantation.

Precision Immunomodulation and Viability era

Paul J. Martin [1] is associated with University of Washington [3] and University of Minnesota [4] during this era. His key contributions include work on the NIH Consensus Development Project criteria for chronic graft-versus-host disease (2014) [7] and a prospective phase III trial of anti–T-lymphocyte globulin assessing chronic GVHD-free survival in HLA-matched unrelated transplantation (2017) [8], which advanced standardized diagnostic criteria and informed precision immunomodulation strategies in transplantation. Stephanie J. Lee [2] is associated with Harvard University [5] and University of Pennsylvania [6] during this era. Her contributions center on the NIH Consensus Development Project criteria for chronic GVHD (2014) [7], which standardized diagnosis and staging to enable precision immunomodulation in transplantation.